We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Novel NanoVelcro Chip Isolates Intact Circulating Tumor Cells for Diagnostic Testing

By LabMedica International staff writers
Posted on 27 Jan 2015
An international team of bioengineers has developed a novel "nanoVelcro" device that removes circulating tumor cells (CTCs) from the blood without damaging them.

Samples of CTCs are regarded as the “liquid biopsy” of a tumor, providing convenient access to all disease sites, including primary tumor and fatal metastases. More...
A method that preserves the integrity of CTCs allows molecular and functional analyses that can guide proper therapeutic intervention.

Investigators at the University of California, Los Angeles (USA) and colleagues at RIKEN Advanced Science Institute (Japan) recently described a novel "nanoVelcro" chip that selectively removes CTCs from the blood. The NanoVelcro Chip is about the size of a postage stamp and is composed of nanowires coated with antibodies that recognize CTCs. When two milliliters of blood are passed through the chip, the tumor cells adhere to the nanowires like Velcro. Efficiency of CTC binding ranges from 40% to 70%. The cancer cells are retained by tiny temperature-responsive polymer brushes inside the device. At 37 degrees Celsius, these polymer brushes stick to the tumor cells, but when cooled to four degrees Celsius, they release them, allowing analysis of the cells.

The investigators were able to successfully demonstrate culture expansion and mutational analysis of CTCs isolated by this purification system. In addition, they adopted the combined use of the Thermoresponsive NanoVelcro system with downstream mutational analysis to monitor the disease evolution of an index non-small-cell lung cancer (NSCLC) patient, highlighting its translational value in managing NSCLC.

“With our new system, we can control the blood’s temperature—the way coffeehouses would with an espresso machine—to capture and then release the cancer cells in great purity,” said senior author Dr. Hsian-Rong Tseng, professor of molecular and medical pharmacology at the University of California, Los Angeles. “We combined the thermoresponsive system with downstream mutational analysis to successfully monitor the disease evolution of a lung cancer patient. This shows the translational value of our device in managing non-small-cell lung cancer with underlying mutations.”

A detailed description of the NanoVelcro Chip was published in the December 13, 2014, online edition of the journal ACS Nano.

Related Links:

University of California, Los Angeles
RIKEN Advanced Science Institute



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Portable POCT Blood Gas Analyzer
BD100
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.